Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/ACTRN12614000628640
ACTRN12614000628640Not yet recruitingPhase 2

For virally-suppressed patients with Chronic Hepatitis B, will GS-9620 as compared to placebo be safer, better tolerated and more efficacious?

Gilead Sciences, Inc.0 sites150 target enrollmentStarted: June 13, 2014Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 2
Status
Not yet recruiting
Enrollment
150
Study OverviewStudy DesignEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomised controlled trial
Primary Purpose
Treatment
Masking
Blinded (masking used)

Eligibility Criteria

Ages
18 Years to 65 Years (—)
Sex
All

Inclusion Criteria

  • •Patients must meet all of the following inclusion criteria to be eligible to participate in the study.
  • •1. Must have the ability to understand and sign a written informed consent form; consent must be obtained prior to initiation of study procedures
  • •2. Adult male and non-pregnant, non-lactating female subjects, (lactating females must agree to discontinue nursing before the study drug is administered), 18–65 years of age inclusive based on the date of the screening visit
  • •3. A negative serum pregnancy test is required for female subjects (unless surgically sterile or greater than two years post-menopausal).
  • •4. Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception.
  • •5. Documented evidence of chronic HBV infection (e.g. HBsAg positive for more than 6 months) with detectable HBsAg levels at screening
  • •6. Have been on approved HBV OAV treatment for greater than or equal to 1 year prior to screening, with HBV DNA below LLOQ (measured at least once) 6 or more months prior to screening, and HBV DNA < 20 IU/ml at screening
  • •7. Subjects currently taking an approved HBV OAV (tenofovir, entecavir, adefovir, lamivudine or telbivudine, either as single agents or in combination) with no change in regimen for 3 months prior to screening
  • •8. Willing to provide blood sample for TLR-7 and IL28B SNP assessment
  • •9. Must be willing and able to comply with all study requirements

Exclusion Criteria

  • •Patients who meet any of the following exclusion criteria are not to be enrolled in the study:
  • •1. Extensive bridging fibrosis or cirrhosis as defined clinically, by imaging or by the following:
  • •a) Metavir greater than or equal to 3 or Ishak fibrosis score greater than or equal to 4 by a liver biopsy within 5 years of screening. or, in the absence of an appropriate liver biopsy, either
  • •b) Screening FibroTest score of > 0.48 and APRI > 1, or
  • •c) Historic FibroScan with a result > 9 kPa within less than than or equal to 6 months of screening (if available)
  • •If liver biopsy is available, the liver biopsy result supersedes (b) and/or (c, if available).
  • •If an appropriate liver biopsy is not available, fibrosis will be evaluated by (b) and/or (c, if available). In the event of discordance between (b) and (c), the FibroScan results will take precedence.
  • •2. Patients meeting any of the following laboratory parameters at screening:
  • •- White Blood cell count < 2500 IU/Ml
  • •- Neutrophil count < 1500 cell/ mm3 (or < 1000 cell/ mm3 if considered a physiological variant in a subject of African descent)
  • •- ALT > 3x the upper limit of normal (ULN)
  • •- INR > ULN unless the subject is stable on an anticoagulant regimen affecting INR
  • •- Albumin < 3.9 g/dL
  • •- Total bilirubin > 2 mg/dl
  • •- Platelet Count < 125,000 /ml
  • •- Estimate creatinine clearance (CLcr) < 50 ml/min (using the Cockcroft-Gault method) based on serum creatinine and actual body weight as measured at the screening evaluation
  • •3. Co-infection with HCV, HIV or HDV
  • •4. Evidence of hepatocellular carcinoma (e.g. as evidenced by recent imaging)
  • •5. Malignancy within 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (e.g. basal cell skin cancer). Subjects under evaluation for possible malignancy are not eligible
  • •6. Significant cardiovascular, pulmonary, or neurological disease
  • •7. Any of the following conditions that may worsen in response to IFN:
  • •- Autoimmune disease (e.g. lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, sarcoidosis, moderate or severe psoriasis)
  • •- Poorly controlled diabetes mellitus
  • •- Significant psychiatric disorders
  • •- Thyroid disorder (unless controlled under treatment)
  • •- Significant pulmonary diseases (e.g. chronic obstructive pulmonary disease)
  • •- Retinal disease
  • •- Immunodeficiency disorders
  • •8. Chronic liver disease of a non-HBV etiology (e.g. hemochromatosis, Wilson’s disease, alpha-1 antitrypsin deficiency, cholangitis)
  • •9. Received solid organ or bone marrow transplant
  • •10. Received prolonged therapy with immunomodulators (e.g. corticosteroids) or biologics (e.g. monoclonal Ab, interferon) within 3 months of screening
  • •11. Use of another investigational agents within 3 months of screening, unless allowed by the Sponsor
  • •12. Current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance
  • •13. Known hypersensitivity to study drug, metabolites or formulation excipients
  • •14. Screening electrocardiogram (ECG) with clinically significant abnormalities and with QTcF interval (QT corrected using Fridericia’s formula) greater than or equal to 450 msec for males and greater than or equal to 470 msec for females
  • •15. Women who may wish to become pregnant during the course of the study
  • •16. Male subjects unwilling to refrain from sperm donation for at least 90 days after the last dose of study drug
  • •17. Use of any prohibited con-medications as described

Investigators

Similar Trials

Completed
Not Applicable
TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C USING ALFA 2B INTERFERON ASSOCIATED WITH RIBAVIRINE, COMPARING IT WITH THE SAME SCHEME PREVIOUS FROM DAILY ADMINISTRATION FOR 2 WEEKS OF ALFA 2 B INTERFERO
PER-014-98SCHERING PLOUGH RESEARCH INSTITUTE,
Recruiting
Not Applicable
Optimization of Antiviral Treatments for Chronic Hepatitis B to Improve Clinical OutcomesCertain infectious and parasitic diseases
KCT0002039Asan Medical Center10,000
Completed
Not Applicable
TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C (HCC) USING PEG-INTERFERON ALPHA 2B AND RIBAVIRINE
PER-039-01SCHERING PLOUGH RESEARCH INSTITUTE,
Not yet recruiting
Not Applicable
ONG-TERM FOLLOW-UP OF HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH INTERFERON ALFA: RELATION TO POLYMORPHISMS IN IL28B AND APOLIPOPROTEIN E LOCI (INTERFERLONG STUDY)liver inflammation1001965410047438chronic hepatitis B
NL-OMON39063Academisch Medisch Centrum135
Completed
Not Applicable
TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS B (HCB) USING PEG-INTERFERON ALPHA 2B
PER-040-01SCHERING PLOUGH RESEARCH INSTITUTE,